Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Michielin

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
The Lancet. Oncology|May 4, 2004
Irinotecan-induced interstitial pneumoniaO Michielin, E Udry, D Périard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2019
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†O Michielin, A C J van Akkooi, P A Ascierto, et al.
Cancer Treatment Reviews|October 16, 2021
Turning tumors from cold to inflamed to improve immunotherapy responseC L Gerard, J Delyon, A Wicky, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 7, 2001
Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexesP Sliz, O Michielin, J C Cerottini, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 11, 2018
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)G Redelman-Sidi, O Michielin, C Cervera, et al.
Revue Medicale Suisse|July 12, 2008
[New developments in cancer immunotherapy]O Michielin, N Rufer, P Romero, et al.
Revue Medicale Suisse|July 9, 2015
[New melanoma immunotherapies: mechanisms of action, efficiency and management of toxicities]B Moura, K Homicsko, G Berthod, et al.
Revue Medicale Suisse|July 5, 2011
[Melanoma: a new therapeutic era]G Berthod, K Homicsko, H Bouchaab, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 29, 2020
Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosisB C Özdemir, S Latifyan, M Perreau, et al.
The Journal of Biological Chemistry|January 28, 1999
T cell recognition of hapten. Anatomy of T cell receptor binding of a H-2kd-associated photoreactive peptide derivativeB Kessler, O Michielin, C L Blanchard, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
The Lancet. Oncology|May 4, 2004
Irinotecan-induced interstitial pneumoniaO Michielin, E Udry, D Périard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2019
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†O Michielin, A C J van Akkooi, P A Ascierto, et al.
Cancer Treatment Reviews|October 16, 2021
Turning tumors from cold to inflamed to improve immunotherapy responseC L Gerard, J Delyon, A Wicky, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 7, 2001
Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexesP Sliz, O Michielin, J C Cerottini, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 11, 2018
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)G Redelman-Sidi, O Michielin, C Cervera, et al.
Revue Medicale Suisse|July 12, 2008
[New developments in cancer immunotherapy]O Michielin, N Rufer, P Romero, et al.
Revue Medicale Suisse|July 9, 2015
[New melanoma immunotherapies: mechanisms of action, efficiency and management of toxicities]B Moura, K Homicsko, G Berthod, et al.
Revue Medicale Suisse|July 5, 2011
[Melanoma: a new therapeutic era]G Berthod, K Homicsko, H Bouchaab, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 29, 2020
Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosisB C Özdemir, S Latifyan, M Perreau, et al.
The Journal of Biological Chemistry|January 28, 1999
T cell recognition of hapten. Anatomy of T cell receptor binding of a H-2kd-associated photoreactive peptide derivativeB Kessler, O Michielin, C L Blanchard, et al.
Pageof 4